NASDAQ:CEMI - Chembio Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.75 -0.15 (-1.69 %)
(As of 05/24/2018 06:03 AM ET)
Previous Close$8.90
Today's Range$8.60 - $8.85
52-Week Range$5.70 - $9.20
Volume16,600 shs
Average Volume24,374 shs
Market Capitalization$126.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21

About Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; and international diagnostics company to develop a POC diagnostic test for a specific type of cancer, as well as with AstraZeneca for the development of a POC assay for a novel biomarker. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Debt-to-Equity RatioN/A
Current Ratio5.17
Quick Ratio3.86

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.01 million
Price / Sales5.16
Cash FlowN/A
Price / CashN/A
Book Value$1.68 per share
Price / Book5.21

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-6,370,000.00
Net Margins-21.28%
Return on Equity-32.21%
Return on Assets-25.72%

Miscellaneous

Employees165
Outstanding Shares14,160,000

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics (NASDAQ:CEMI) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.09. The company earned $7.72 million during the quarter, compared to analyst estimates of $6.10 million. Chembio Diagnostics had a negative net margin of 21.28% and a negative return on equity of 32.21%. View Chembio Diagnostics' Earnings History.

Who are some of Chembio Diagnostics' key competitors?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:
  • Mr. John J. Sperzel III, B.Sc., CEO, Pres & Director (Age 54)
  • Mr. Neil A. Goldman, Exec. VP & CFO
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 51)
  • Ms. Sharon Klugewicz, Pres of Americas Region (Age 50)
  • Dr. Robert Passas Ph.D., Pres of EMEA & APAC Regions (Age 64)

Has Chembio Diagnostics been receiving favorable news coverage?

Headlines about CEMI stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chembio Diagnostics earned a coverage optimism score of 0.15 on Accern's scale. They also gave media coverage about the company an impact score of 47.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include Acuta Capital Partners LLC (14.17%), ARS Investment Partners LLC (6.07%), Cortina Asset Management LLC (3.70%), Gagnon Securities LLC (1.42%), Wells Fargo & Company MN (0.99%) and Gagnon Advisors LLC (0.92%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Neil A Goldman, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.

Which institutional investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC. View Insider Buying and Selling for Chembio Diagnostics.

Which institutional investors are buying Chembio Diagnostics stock?

CEMI stock was acquired by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Acuta Capital Partners LLC, Gagnon Securities LLC, Gagnon Advisors LLC, Wells Fargo & Company MN and Benchmark Capital Advisors. Company insiders that have bought Chembio Diagnostics stock in the last two years include Neil A Goldman and Norman H Pessin. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $8.75.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $126.05 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (CEMI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chembio Diagnostics (NASDAQ:CEMI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Chembio Diagnostics (NASDAQ:CEMI) Consensus Price Target History

Price Target History for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2016BenchmarkSet Price TargetBuy$9.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Chembio Diagnostics (NASDAQ:CEMI) Earnings History and Estimates Chart

Earnings by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.08)($0.08)($0.08)
Q3 20181($0.08)($0.08)($0.08)
Q4 20181($0.04)($0.04)($0.04)

Chembio Diagnostics (NASDAQ CEMI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.14)($0.0490)$6.10 million$7.72 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.10)($0.16)$5.66 million$5.99 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.11)($0.05)$5.65 million$7.59 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.1650)($0.18)$4.96 million$2.89 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.1950)($0.1320)$4.88 million$5.43 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.15)($0.21)$4.44 million$4.26 millionViewListenView Earnings Details
11/10/2016Q3 2016($0.17)($0.19)$3.76 million$3.75 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.86)$6.72 million$3.27 millionViewListenView Earnings Details
5/12/2016Q1($0.09)($0.03)$4.83 million$6.60 millionViewListenView Earnings Details
3/8/2016Q4($0.09)($0.07)$6.56 million$4.42 millionViewN/AView Earnings Details
11/12/2015Q3($0.09)($0.05)$6.77 million$6.89 millionViewListenView Earnings Details
8/6/2015Q2($0.03)($0.07)$7.53 million$6.72 millionViewN/AView Earnings Details
5/7/2015Q115($0.08)($0.07)$5.20 million$6.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.04)($0.05)$7.10 million$7.10 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.03)($0.03)$7.71 million$7.31 millionViewN/AView Earnings Details
8/7/2014Q2($0.02)($0.02)$6.25 million$7.42 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.02)($0.02)$6.87 million$5.81 millionViewN/AView Earnings Details
3/6/2014Q413$0.04($0.03)$7.05 million$7.86 millionViewN/AView Earnings Details
11/7/2013Q3 2013$0.06$0.07$8.59 million$9.62 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.04)($0.03)$5.56 million$5.39 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.06$0.04$7.47 million$6.31 millionViewN/AView Earnings Details
3/7/2013Q4 2012$0.07$0.06ViewN/AView Earnings Details
11/13/2012Q312$0.04($0.04)$6.11 million$5.01 millionViewN/AView Earnings Details
8/9/2012$0.05$0.04ViewN/AView Earnings Details
5/8/2012Q1 2012$0.08$0.05ViewN/AView Earnings Details
3/8/2012Q4 2011$0.08$0.06ViewN/AView Earnings Details
11/3/2011Q3 2011$0.06ViewN/AView Earnings Details
8/4/2011Q2 2011$0.02ViewN/AView Earnings Details
5/5/2011Q1 2011($0.02)ViewN/AView Earnings Details
3/3/2011Q4 2010$0.22ViewN/AView Earnings Details
11/4/2010Q3 2010$0.02ViewN/AView Earnings Details
7/29/2010Q2 2010($0.08)$0.07ViewN/AView Earnings Details
5/6/2010Q1 2010($0.02)ViewN/AView Earnings Details
3/5/2010Q4 2009$0.02ViewN/AView Earnings Details
11/4/2009Q3 2009$0.03ViewN/AView Earnings Details
5/8/2009Q1 2009($0.08)ViewN/AView Earnings Details
11/12/2008Q3 2008($0.08)($0.03)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.08)($0.08)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.80)($2.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Chembio Diagnostics (NASDAQ:CEMI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Chembio Diagnostics (NASDAQ CEMI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.65%
Institutional Ownership Percentage: 41.60%
Insider Trading History for Chembio Diagnostics (NASDAQ:CEMI)
Insider Trading History for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ CEMI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Neil A GoldmanCFOBuy14,815$6.75$100,001.2514,815View SEC Filing  
6/28/2017Norman H PessinInsiderBuy36,250$5.48$198,650.00View SEC Filing  
6/15/2016Sharon W KlugewiczCOOSell3,000$8.40$25,200.007,000View SEC Filing  
6/1/2016Javan EsfandiariInsiderSell25,000$8.58$214,500.0079,110View SEC Filing  
5/29/2015Javan EsfandiariInsiderSell20,000$4.50$90,000.00View SEC Filing  
11/19/2014Peter KissingerDirectorBuy1,800$4.31$7,758.00View SEC Filing  
2/26/2014Sharon W KlugewiczCOOBuy10,000$3.50$35,000.00View SEC Filing  
12/6/2013Javan EsfandiariSVPSell10,000$3.40$34,000.00View SEC Filing  
11/11/2013Lawrence A SiebertMajor ShareholderSell30,000$3.63$108,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chembio Diagnostics (NASDAQ CEMI) News Headlines

Source:
DateHeadline
Chembio Diagnostics and Massachusetts General Hospital Enter Memorandum Of Understanding to Develop Point-of-Care Fever Diagnostic TestChembio Diagnostics and Massachusetts General Hospital Enter Memorandum Of Understanding to Develop Point-of-Care Fever Diagnostic Test
finance.yahoo.com - May 22 at 9:25 AM
Chembio Diagnostics Names John Potthoff, Ph.D. to its Board of DirectorsChembio Diagnostics Names John Potthoff, Ph.D. to its Board of Directors
finance.yahoo.com - May 16 at 9:54 AM
CEMI: Q1 2018: Product Sales Off To Strong Start, And Should Steepen From HereCEMI: Q1 2018: Product Sales Off To Strong Start, And Should Steepen From Here
finance.yahoo.com - May 14 at 10:34 AM
Chembio Diagnostics (CEMI) CEO John Sperzel on Q1 2018 Results - Earnings Call TranscriptChembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:22 AM
Chembio Diagnostics (CEMI) Releases Quarterly  Earnings Results, Beats Estimates By $0.09 EPSChembio Diagnostics (CEMI) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - May 11 at 5:41 PM
Chembio Diagnostics beats by $0.09, beats on revenueChembio Diagnostics beats by $0.09, beats on revenue
seekingalpha.com - May 10 at 9:52 AM
Edited Transcript of CEMI earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:52 AM
Should You Buy Chembio Diagnostics Inc (NASDAQ:CEMI) At $7.95?Should You Buy Chembio Diagnostics Inc (NASDAQ:CEMI) At $7.95?
finance.yahoo.com - May 9 at 4:21 PM
Chembio Diagnostics Reports First Quarter 2018 Financial ResultsChembio Diagnostics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 4:21 PM
Chembio Diagnostics (CEMI) Scheduled to Post Quarterly Earnings on WednesdayChembio Diagnostics (CEMI) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 9:42 PM
Wired News – Chembio Signs Collaboration Agreement with LumiraDx to Develop New Point-of-Care Diagnostic TestsWired News – Chembio Signs Collaboration Agreement with LumiraDx to Develop New Point-of-Care Diagnostic Tests
finance.yahoo.com - April 27 at 10:13 AM
Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018Chembio Diagnostics to Report First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - April 26 at 4:19 PM
Chembio teams up with LumiraDx to develop POC tests for infectious diseasesChembio teams up with LumiraDx to develop POC tests for infectious diseases
seekingalpha.com - April 25 at 4:29 PM
Chembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious DiseasesChembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious Diseases
globenewswire.com - April 25 at 9:48 AM
Chembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious DiseasesChembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious Diseases
finance.yahoo.com - April 25 at 9:47 AM
Chembio Diagnostics (CEMI) Upgraded to Sell at ValuEngineChembio Diagnostics (CEMI) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
Chembio Diagnostics (CEMI) Lifted to "Buy" at ValuEngineChembio Diagnostics (CEMI) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
Edited Transcript of CEMI earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 30 at 9:47 AM
Q1 2018 Earnings Estimate for Chembio Diagnostics Inc Issued By Zacks Investment Research (CEMI)Q1 2018 Earnings Estimate for Chembio Diagnostics Inc Issued By Zacks Investment Research (CEMI)
www.americanbankingnews.com - March 16 at 8:37 AM
CEMI: Q4 2017: Strategic Successes and Recent Wins Sets Up 2018 To Be Another Strong YearCEMI: Q4 2017: Strategic Successes and Recent Wins Sets Up 2018 To Be Another Strong Year
finance.yahoo.com - March 14 at 10:44 AM
Chembio Diagnostics (CEMI) Announces  Earnings ResultsChembio Diagnostics (CEMI) Announces Earnings Results
www.americanbankingnews.com - March 9 at 2:03 PM
Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial ResultsChembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 5:06 PM
Neil A. Goldman Purchases 14,815 Shares of Chembio Diagnostics Inc (CEMI) StockNeil A. Goldman Purchases 14,815 Shares of Chembio Diagnostics Inc (CEMI) Stock
www.americanbankingnews.com - February 13 at 3:18 PM
Chembio Diagnostics (CEMI) Prices 1.78M Share Common Offering at $6.75/ShChembio Diagnostics (CEMI) Prices 1.78M Share Common Offering at $6.75/Sh
www.streetinsider.com - February 10 at 8:57 AM
Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial ResultsChembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results
finance.yahoo.com - February 9 at 9:05 AM
Chembio Diagnostics Announces Proposed Public Offering of Common StockChembio Diagnostics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 9 at 9:05 AM
Chembio Diagnostics Announces Pricing of its Public Offering of Common StockChembio Diagnostics Announces Pricing of its Public Offering of Common Stock
finance.yahoo.com - February 9 at 9:05 AM
ETFs with exposure to Chembio Diagnostics, Inc. : December 28, 2017ETFs with exposure to Chembio Diagnostics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:57 PM
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:55 PM
Chembio Diagnostics (CEMI) Names Neil A. Goldman as Chief Financial OfficerChembio Diagnostics (CEMI) Names Neil A. Goldman as Chief Financial Officer
www.streetinsider.com - December 21 at 5:25 PM
Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis SystemChembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System
finance.yahoo.com - December 21 at 9:23 AM
Chembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial OfficerChembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial Officer
finance.yahoo.com - December 20 at 9:25 AM
Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic TestChembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test
www.nasdaq.com - December 19 at 9:24 AM
Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic TestChembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test
finance.yahoo.com - December 19 at 9:24 AM
Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.s FY2018 Earnings (CEMI)Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.'s FY2018 Earnings (CEMI)
www.americanbankingnews.com - December 11 at 10:50 AM
CEMI: Moving PT to $15.5/Share On Upward Revenue Revisions, Comp Multiple ExpansionCEMI: Moving PT to $15.5/Share On Upward Revenue Revisions, Comp Multiple Expansion
finance.yahoo.com - December 7 at 5:53 PM
Chembio Receives $4.2 Million in Accounts Receivable Payments from Bio-ManguinhosChembio Receives $4.2 Million in Accounts Receivable Payments from Bio-Manguinhos
www.nasdaq.com - December 6 at 9:33 AM
Chembio Diagnostics (CEMI) Secures $8.5M Commitment from Bio-Manguinhos to Purchase Components for Production of DPP Assays in 2018Chembio Diagnostics (CEMI) Secures $8.5M Commitment from Bio-Manguinhos to Purchase Components for Production of DPP Assays in 2018
www.streetinsider.com - December 6 at 9:33 AM
Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018
finance.yahoo.com - December 5 at 10:04 AM
CEMI: DPP HIV/Syph, Several DPP Fever Products to Drive 2018 GrowthCEMI: DPP HIV/Syph, Several DPP Fever Products to Drive 2018 Growth
finance.yahoo.com - November 20 at 6:13 PM
Edited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 7:55 PM
ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 7:55 PM
CHEMBIO DIAGNOSTICS, INC. to Host Earnings CallCHEMBIO DIAGNOSTICS, INC. to Host Earnings Call
finance.yahoo.com - November 8 at 8:42 PM
Chembio Diagnostics Reports Third Quarter 2017 Financial ResultsChembio Diagnostics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 8:42 PM
Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017
finance.yahoo.com - November 7 at 8:03 PM
Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial ResultsChembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results
feeds.benzinga.com - November 1 at 9:28 AM
ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 3:41 PM
ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 5:50 PM
ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 11:39 AM
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 12:24 PM

SEC Filings

Chembio Diagnostics (NASDAQ:CEMI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Chembio Diagnostics (NASDAQ:CEMI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Chembio Diagnostics (NASDAQ CEMI) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.